The transient CEA increase that we observed could thus, in part, reflect the killing of the tumour cells, but the late timing of the mid-adjuvant blood sample (≥3 months after starting chemotherapy) suggests that other mechanisms may also contribute. This evidence concerns the gene CEACAM5 and neoplasm.